Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653)

Market Cap	36.88B
Revenue (ttm)	3.72B
Net Income (ttm)	476.19M
Shares Out	1.11B
EPS (ttm)	0.43
PE Ratio	76.96
Forward PE	58.20
Dividend	0.29 (0.87%)
Ex-Dividend Date	Sep 18, 2024

Volume	3,882,936
Open	33.29
Previous Close	33.82
Day's Range	33.29 - 34.50
52-Week Range	18.59 - 40.66
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 12, 2025

About Haisco Pharmaceutical Group

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,448
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2023, Haisco Pharmaceutical Group's revenue was 3.36 billion, an increase of 11.27% compared to the previous year's 3.02 billion. Earnings were 295.11 million, an increase of 6.51%.